Skip to main content
. 2022 Nov 14;14(22):5597. doi: 10.3390/cancers14225597

Figure 3.

Figure 3

FK866 cooperates with metformin to reduce metabolic compensation. (A) Quantification of NAD+/NADH ratio in KP4 and PANC-1 cells treated for 6 h with 10 mM metformin, 5 nM FK866, a combination of metformin and FK866, or vehicle. (B) Quantification of total NAD levels after 6 h or 24 h in KP4 cells treated with 10 mM metformin, 5 nM FK866, Met+FK866, or vehicle. Values are means of triplicates ± SEM. * p-value ≤ 0.05, ** p-value ≤ 0.01, *** p-value ≤ 0.001, **** p-value ≤ 0.0001, NS, not significant (ANOVA), n = 3. (C) ECAR (extracellular acidification rate) and OCR (oxygen consumption rate) of KP4 cells treated with 10 mM metformin, measured by SeaHorse analysis. Cells were either pre-treated or not with FK866 (5 nM) for 18 h prior to SeaHorse analysis in order to deplete NAD levels. Values are means of triplicates ± SEM, n = 3.